Sanofi Announces Call for Submissions for Ignite: The Diabetes Ideas Challenge

Paris (ots/PRNewswire) -

- Worldwide invitation to create and submit concepts

for a potential next-generation insulin delivery device -

Sanofi announced today that it is accepting submissions for
Ignite: The Diabetes Ideas Challenge ("Ignite Challenge"). The
web-based Ignite Challenge invites patients, caregivers, designers,
engineers, and innovators from around the globe to submit ideas that
could shape the features and design of a next-generation, insulin
delivery device for people with diabetes. Building on the user
experience and technology advances of the past 30 years, the Ignite
Challenge seeks to address the critical need for innovative,
easy-to-use and cost-effective devices for delivering injectable
medications for the treatment of diabetes.

"Over time and across geographies, we observe a consistent
increase in the use of injectable medications among the more than 370
million people living with diabetes," said Pierre Chancel, Senior
Vice President, Global Diabetes, Sanofi. "Through innovation
challenges such as the Ignite Challenge, Sanofi hopes to foster
creative thinking and new ideas that may improve the way people
manage their diabetes in the future using patient-friendly and
innovative devices."

Many people living with diabetes use insulin and an insulin
delivery device as part of their overall treatment plan, which may
include other medications, along with a healthy diet and exercise.
The Ignite Challenge turns to innovators to submit ideas that may
advance the technology and design of today's insulin delivery
devices, while maintaining key factors including reliability, ease of
use and aesthetic appeal. The Ignite Challenge will award ten winning
submissions $5,000 each for their original ideas.

Challenge concept submissions must meet the following three
criteria:

- Accessibility - concept must be usable by a broad population, including
the young and old, or people with impaired hand use or vision.
- Appropriateness - concept must be easy to integrate into daily life and be of
high quality. Device should be portable and aesthetically pleasing. It has to be
recognizable as an injection device, while not appearing overtly medical.
- Functionality - Device must meet functional requirements as a medical tool,
should enable accurate delivery, have functionality for extended periods without
electricity, and the ability to store more than one dose of insulin per disposable
device.

"Sanofi understands the importance of going beyond the molecule to
help people manage the complex challenges of diabetes," said
Christoph Heinemann, Vice President Strategy and Portfolio
Management, Global Diabetes, Sanofi. "While we are committed to our
current and award-winning insulin delivery device offerings, we
understand the importance of exploring new, innovative approaches
that may take years to develop and test but that could provide
additional offerings to people living with diabetes."

Over the past few years, innovation challenges have become an
integral part of Sanofi's commitment to diabetes care. This year
marks the company's third annual Data Design Diabetes(TM) Innovation
Challenge in the U.S., which has a three-part aim: innovation in the
quality, delivery, and cost of diabetes care. Sanofi U.S. also
developed the Partners in Patient Health Collaborate - Activate
Innovation Challenge in 2012, which awarded teams that delivered
novel approaches to better engage patients in healthcare. The Ignite
Challenge continues this momentum by encouraging the development of
solutions that show potential to directly meet patients' needs.

The full timeline for the Ignite Challenge is as follows:

Open Submissions: April 8 - May 10

The Ignite Challenge website [http://www.igniteideaschallenge.com
] is open for submissions and will remain open until May 10, 2013.

Submission Review and Judging: May 13 - May 24

An expert panel of judges will review the Ignite Challenge
submissions.

Winner Announcements: May 30

Ten winners will be announced and each awarded $5,000.

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insights that come from listening to
and engaging with people living with diabetes, the Company is forming
partnerships to offer diagnostics, therapies, services and devices,
including intelligent blood glucose monitoring systems. Sanofi
markets both injectable and oral medications for people with type 1
or type 2 diabetes.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, consumer healthcare, emerging markets, animal
health and the new Genzyme. Sanofi is listed in Paris and in New
York .

Forward-Looking Statements

This press release contains forward-looking statements.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements
are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions.
Although Sanofi's management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject
to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could cause
actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the
Group's ability to benefit from external growth opportunities, trends
in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2012. Other than as
required by applicable law, Sanofi does not undertake any obligation
to update or revise any forward-looking information or statements.

ots Originaltext: Sanofi Diabetes
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Media Relations : Marisol Peron, Tel.:
+(33)1-53-77-46-46, marisol.peron@sanofi.com ; Global Diabetes
Division
Communications, Tilmann Kiessling, Tel.: + (49)1-72-61-59-29-1,
tilmann.kiessling@sanofi.com